Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors 2021-06-21 15:15
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021 2021-06-07 08:00
Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016 2016-06-06 20:30
1